ArticleHeliyon2022

An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.

Mohamed S Abdelbaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.